Skip to main content
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Jinan Liu, PhD
Authored Items
The Effects of a Sitagliptin Formulary Restriction Program on Diabetes Medication Use
Yuexin Tang, PhD
,
Quang T. Nguyen, DO, FACE, FTOS
,
Xingyue Huang, PhD
,
Jinan Liu, PhD
,
R. Ravi Shankar, MD
,
Michael L. Ganz, PhD
,
Swapnil Rajpathak, MD, DrPH
December 2017 Vol 10, No 9
in
Original Research
,
Practice Management
Considering Patient Preferences When Selecting Anti–Tumor Necrosis Factor Therapeutic Options
Andrea DeVries, PhD
,
Jinan Liu, PhD
,
Albert Tzeel, MD, MHSA, CPE, FAAPL
,
Alexander P. Ruggieri, MD, MHS
,
Judith J. Stephenson, SM
,
Gosia Sylwestrzak, MA
April 2014 Vol 7, No 2
in
Original Research
Last modified: April 23, 2019